Adage Capital Partners’s ProQR Therapeutics PRQR Stock Holding History

Adage Capital Partners’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.1M	Hold	6,253,467	–	–	0.02%	683
2025 Q4	$12.6M	Hold	6,253,467	–	–	0.02%	617
2025 Q3	$13.3M	Sell	6,253,467 -348,471	-5%	-$761K	0.02%	577
2025 Q2	$13.5M	Sell	6,601,938 -1,500,160	-19%	-$2.44M	0.02%	550
2025 Q1	$10.8M	Sell	8,102,098 -1,500,182	-16%	-$3.19M	0.02%	571
2024 Q4	$25.4M	Buy	9,602,280 +5,976,813	+165%	+$19M	0.04%	376
2024 Q3	$6.6M	Hold	3,625,467	–	–	0.01%	684
2024 Q2	$6.02M	Hold	3,625,467	–	–	0.01%	689
2024 Q1	$8.3M	Hold	3,625,467	–	–	0.02%	633
2023 Q4	$7.18M	Hold	3,625,467	–	–	0.01%	646
2023 Q3	$4.71M	Hold	3,625,467	–	–	0.01%	671
2023 Q2	$5.87M	Hold	3,625,467	–	–	0.01%	652
2023 Q1	$7.72M	Hold	3,625,467	–	–	0.02%	660
2022 Q4	$13.4M	Buy	3,625,467 +325,467	+10%	+$426K	0.03%	557
2022 Q3	$2.46M	Hold	3,300,000	–	–	0.01%	842
2022 Q2	$2.57M	Hold	3,300,000	–	–	0.01%	866
2022 Q1	$2.99M	Sell	3,300,000 -1,415,152	-30%	-$4.74M	0.01%	874
2021 Q4	$37.8M	Hold	4,715,152	–	–	0.07%	292
2021 Q3	$39.5M	Buy	4,715,152 +20,687	+0.4%	+$135K	0.08%	257
2021 Q2	$31.6M	Hold	4,694,465	–	–	0.06%	326
2021 Q1	$31M	Buy	4,694,465 +144,403	+3%	+$738K	0.06%	320
2020 Q4	$19.1M	Hold	4,550,062	–	–	0.04%	424
2020 Q3	$21.8M	Hold	4,550,062	–	–	0.05%	352
2020 Q2	$27.7M	Hold	4,550,062	–	–	0.07%	305
2020 Q1	$25M	Sell	4,550,062 -21,257	-0.5%	-$163K	0.07%	273
2019 Q4	$45.3M	Buy	4,571,319 +835,812	+22%	+$6.51M	0.11%	225
2019 Q3	$21.5M	Hold	3,735,507	–	–	0.05%	349
2019 Q2	$34M	Hold	3,735,507	–	–	0.08%	266
2019 Q1	$51.8M	Hold	3,735,507	–	–	0.13%	194
2018 Q4	$58.9M	Buy	3,735,507 +273,566	+8%	+$5.02M	0.16%	164
2018 Q3	$67M	Buy	3,461,941 +1,299,414	+60%	+$13.8M	0.15%	172
2018 Q2	$15.8M	Buy	2,162,527 +662,527	+44%	+$3.34M	0.04%	464
2018 Q1	$4.61M	Buy	1,500,000 +500,000	+50%	+$1.61M	0.01%	644
2017 Q4	$3.23M	Buy	+1,000,000	New	+$3.59M	0.01%	649

Other funds holding PRQR

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Adage Capital Partners's PRQR Position: Q1 2026 in Review

Adage Capital Partners held its ProQR Therapeutics (PRQR) position steady in Q1 2026 at 6,253,467 shares worth $10.1M. The position accounts for 0.02% of the portfolio, ranked #683.

Adage Capital Partners first reported a position in PRQR in Q4 2017 and has held it in 34 quarters since. The position peaked at $67M in Q3 2018. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Adage Capital Partners held 6,253,467 shares of ProQR Therapeutics worth $10.1M as of Q1 2026.
Adage Capital Partners left its ProQR Therapeutics share count unchanged in Q1 2026.
ProQR Therapeutics made up 0.02% of Adage Capital Partners's portfolio in Q1 2026, its #683 holding.
Adage Capital Partners first reported a position in ProQR Therapeutics in Q4 2017 and has held it in 34 quarters since.
Adage Capital Partners's ProQR Therapeutics position peaked at $67M in Q3 2018.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.